A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
2,004
90mg/tablet, 1 tablet bid
Bleeding Events
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal
Time frame: 12 months
Serious Adverse Events Other Than Bleeding
SAEs except the blending events which have aleady been reported as SAEs.
Time frame: 12 months
Major CV Events
Combination of CV death, MI, and stroke
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Chengdu, China
Research Site
Chuangchun, China
Research Site
Fuzhou, China
...and 29 more locations